Illumina Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Illumina Inc 's ROA in the third quarter of 2026?
Illumina Inc achieved a return on average assets (ROA) of 13.39 % in its third quarter of 2026, this is above ILMN's average return on assets of 4.29%.
Illumina Inc s assets during the 12 months ending in the third quarter of 2026 are valued at $6 billion

ROA has improved compared to 12.64% in the second quarter of 2026, due to net income growth.

However, within the Healthcare sector 69 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 27 2026 quarter, so far to 418, from total ROA ranking in the second quarter of 2026 at 467.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 27 2026) III. Quarter	(Jun 28 2026) II. Quarter	(Mar 29 2026) I. Quarter	(Dec 28 2025) IV. Quarter	(Sep 28 2025) III. Quarter
Y / Y Total Assets Change	10.28 %	9.25 %	6.1 %	26.48 %	24.94 %
Y / Y Net Income Change	46.67 %	-11.91 %	2.29 %	79.57 %	-78.72 %
Net Income (TTM) in million	895	825	853	850	702
Return On Assets (TTM)	13.39 %	12.64 %	13.36 %	13.51 %	11.82 %
ILMN's Total Ranking	# 418	# 467	# 544	# 231	# 3537
Total Assets (TTM) in million	6,812	6,650	6,559	6,725	6,177
Seq. Total Assets Change	2.44 %	1.39 %	-2.47 %	8.87 %	1.48 %
Seq. Net Income Change	6.28 %	54.48 %	-59.88 %	122.67 %	-36.17 %

ILMN's 5 Years Annual ROA >> Back to ILMN Management Effectiveness >> Compare ILMN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 2
Sector	# 70
Overall	# 410

Return On Assets Statistics
High	Average	Low
20.45 %	4.29 %	-35.56 %
(Jun 29 2025)		(Jul 02 2023)

Financial Statements
Illumina Inc 's Assets	$ 6,812 million	ILMN's Balance sheet
Illumina Inc 's Income	$ 220 million	Quarterly ILMN's Income Statement
ILMN's Income by Division		See ILMN's Income by Division

Annual Return On Assets	(Dec 28 2025) FY 2025	(Dec 29 2024) FY 2024	(Dec 31 2023) FY 2023	(Jan 01 2023) FY 2022	(Jan 02 2022) FY 2021
Y / Y Total Assets Change	24.96 %	-44.42 %	-17.52 %	-20.25 %	106.81 %
Total Assets in million	6,644	5,317	9,567	11,599	14,545
Y / Y Net Income Change	-	-	-	-	16.16 %
Net Income in million	850	-1,223	-1,161	-4,404	762
Annual Return On Assets	12.79 %	-23 %	-12.14 %	-37.97 %	5.24 %

ILMN's 5 Years Annual ROA >> Back to ILMN Management Effectiveness >> Compare ILMN ROA to its Competitors

Comment on ILMN's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 12.79 % compared to prior year, due to annual net income growth of % to $850.00 million, while value of Illumina Inc 's overall assets grew just by 24.96 % to $6,644.00 million, compared to $6,644.00 a year before.

More Return On Assets Ratios
ILMN's' Return on Assets at Yahoo Finance
Laboratory Analytical Instruments Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ILMN's Roa Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ILMN's Competitors
Subscribers only: Roa for Illumina Inc 's Suppliers
Subscribers only: Return On Assets for ILMN's Customers

You may also want to know
ILMN's Roi	ILMN's Inventory Turnover Ratio	ILMN's Growth Rates	ILMN's Dividend Comparisons
	ILMN's Profitability Ratios	ILMN's Asset Turnover Ratio	ILMN's Dividend Growth
ILMN's Roe	ILMN's Valuation Ratios	ILMN's Financial Strength Ratios	ILMN's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 27 2026, within Healthcare Sector	ROA
Indivior Pharmaceuticals Inc	36.35 %
Rallybio Corporation	34.55 %
Idexx Laboratories Inc	34.05 %
Zevra Therapeutics Inc	26.33 %
Caredx Inc	25.74 %
Medpace Holdings Inc	24.47 %
Acadia Pharmaceuticals Inc	21.60 %
Standard Biotools Inc	21.56 %
Eli Lilly And Company	21.24 %
Iradimed Corporation	20.89 %
Resmed Inc	18.67 %
Alector Inc	18.37 %
Corcept Therapeutics Inc	18.09 %
Chemed Corporation	17.73 %
Halozyme Therapeutics Inc	17.26 %
Pro dex Inc	16.75 %
Denali Therapeutics Inc	16.42 %
Krystal Biotech Inc	15.48 %
West Pharmaceutical Services Inc	15.47 %
Dexcom Inc	15.47 %
Intuitive Surgical Inc	14.71 %
Vertex Pharmaceuticals Inc	14.16 %
Neurocrine Biosciences Inc	13.69 %
Illumina Inc	13.43 %
Healthcare Services Group Inc	12.79 %
Kiniksa Pharmaceuticals International Plc	12.64 %
Tenet Healthcare Corp	12.39 %
Hca Healthcare Inc	11.73 %
Carlisle Companies Incorporated	11.72 %
Regeneron Pharmaceuticals Inc	11.50 %

Date modified: 2026-10-31T09:55:44+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.